RCM
HRTX icon

Rotella Capital Management’s Heron Therapeutics HRTX Stock Holding History

Rotella Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-13,023
Closed -$189K – 496
2015
Q1 		$189K Buy
+13,023
New +$147K 0.16% 230

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Rotella Capital Management's HRTX Position: Q2 2015 in Review

Rotella Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2015, closing a stake of 13,023 shares — an estimated $189K sold.

Rotella Capital Management first reported a position in HRTX in Q1 2015 and held it in 1 quarter. The position peaked at $189K in Q1 2015. 88 funds tracked by Wall St. Rank hold HRTX as of Q2 2015.

  • Rotella Capital Management reported no remaining Heron Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Rotella Capital Management sold 13,023 Heron Therapeutics shares in Q2 2015, an estimated $189K.
  • Rotella Capital Management first reported a position in Heron Therapeutics in Q1 2015 and held it in 1 quarter.
  • Rotella Capital Management's Heron Therapeutics position peaked at $189K in Q1 2015.
  • 88 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2015.

Based on Rotella Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.